Cargando…
Epstein-Barr Virus (EBV) Prevalence and the Risk of Reactivation in Patients with Inflammatory Arthritis Using Anti-TNF Agents and in those who are Biologic Naive
OBJECTIVE: Anti-TNF agents (etanercept, infliximab and adalimumab) are widely used in inflammatory conditions, such as rheumatoid arthritis; however, they are not without side effects, potentially including lymphoma. We compared Epstein-Barr virus (EBV) levels in patients with inflammatory arthritis...
Autores principales: | McKeown, Emily, Pope, Janet E, Leaf, Suzanne |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714577/ https://www.ncbi.nlm.nih.gov/pubmed/19639039 http://dx.doi.org/10.2174/1874312900903010030 |
Ejemplares similares
-
Perspective: Contribution of Epstein–Barr virus (EBV) Reactivation to the Carcinogenicity of Nasopharyngeal Cancer Cells
por: Wu, Chung-Chun, et al.
Publicado: (2018) -
Epstein–Barr Virus (EBV) Rta-Mediated EBV and Kaposi's Sarcoma-Associated Herpesvirus Lytic Reactivations in 293 Cells
por: Chen, Yen-Ju, et al.
Publicado: (2011) -
Epstein-Barr Virus (EBV)-Associated Haemophagocytic Syndrome
por: Torti, Lorenza, et al.
Publicado: (2012) -
Epstein-Barr Virus (EBV)-associated Gastric Carcinoma
por: Iizasa, Hisashi, et al.
Publicado: (2012) -
Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV
por: Venturini, Cristina, et al.
Publicado: (2021)